DOCKET NO.: 239770US0DIV

DEC 2 9 2006

IN THE UNITED STA

IN RE APPLICATION OF:

David LEWIS et al

SERIAL NO:

10/612,067 July 3, 2003 **GROUP ART UNIT: 1616**

D TRADEMARK OFFICE

EVAMBLED

EXAMINER: HAGHIGHATIAN, M.

FILED: FOR:

PHARMACEUTICAL AEROSOL COMPOSITION

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR

Applicants wish to disclose the following information.

REFERENCES

- The Applicants wish to make of record the references listed on the attached Form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 C.F.R. §1.17(p).

RELATED CASES

- Attached is a list of Applicants' pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 C.F.R. §1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached Form PTO-1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 C.F.R. §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to Deposit Account No. <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Stephen G. Baxter

Registration No. \32,884

01/03/2007 JADDO1 /0000002 10612067

01 FC:1806

189.69 OP

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE				ATTY DOCKET NO.		SERIAL NO.		
				239770US0DIV 10/612,067				
OIPE			APPLICANT					
LIST OF REFERENCES CITED BY APPLICANT			David LEWIS et al	· · · · · ·	-			
(DEC 2 9 2006)			9 2006	FILING DATE		GROUP		
		12/2		July 3, 2003		1616		
		A REAL PROPERTY OF THE PARTY OF	DEMARKOR	U.S. PATENT DOCUMENTS	,			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS		ILING DATE PPROPRIATE
	AA	6,290,930	09/18/01	Frank E. BLONDINO et al				
	AB	5,653,961	08/05/97	Rebecca A. McNALLY et al				
	AC	6,451,285	09/17/02	Frank E. BLONDINO et al				
	AD	2003/0077230 A1	04/24/03	Frank E. BLONDINO et al				
	AE	6,645,466	11/11/03	Manfred KELLER et al				
	AF	6,149,892	11/21/00	Ignatius Loy BRITTO				
	AG	5,695,743	12/09/97	Tarlochan S. PUREWAL et al				
	АН	5,683,677	11/04/97	Tarlochan S. PÜREWAL et al				
	ΑI	6,026,808	02/22/00	Thomas Alex ARMER et al				
	AJ	6,045,778	04/04/00	Paul Donald JAGER et al				
	AK	6,006,745	12/28/99	Paul E. MARECKI et al				
	AL	5,954,047	09/21/99	Thomas Alex ARMER et al				
	АМ	5,435,297	07/25/95	Christoph KLEIN				
	AN	3,361,306	01/02/68	W. M. GRIM				
FOREIGN PATENT DOCUME				REIGN PATENT DOCUMENTS				
		DOCUMENT	DATE	COUNTRY			TRANS	LATION
		NUMBER				YES	<u>; </u>	NO
	AO	WO 98/56349	12/17/98	WIPO				
	AP	WO 98/34595	08/13/98	WIPO				
	AO	WO 92/11236	07/09/92	WIPO				
	AR	WO 96/32150	10/17/96	WIPO			\longrightarrow	
	AS	WO 96/32151	10/17/96	WIPO				
	AT	WO 96/32345	10/17/96	WIPO				
	AU		06/29/95	WIPO			\longrightarrow	
	AV	0 504 112 A2	09/16/92	EPO (English Abstract provided)				XXX
		OTHER RE	FERENCES (Including Author, Title, Date, Pertinent	Pages, e	tc.)		
	AW			epoxy aerosol can lining exposed to hydi ND BIOPHARMACEUTICS, Vol. 44, pp.			lants", E	UROPEAN
	AX	ABPI COMPENDIUM (Limited, London, pp. 8	OF DATA SHE 1-82, (1996-97	ETS AND SUMMARIES OF PRODUCT.	CHARACT	ERISTICS	, Datap	harm Publications
	Paul A. Sanders, Ph.D., "Homogeneous Systems and Their Properties", <u>HANDBOOK OF AEROSOL TECHNOLOGY</u> , Second Edition, Van Nostrand Reinhold Company, NY, pg. 30, 1979.							
	AZ G. Brambilla et al, "Modulation of Aerosol Clouds Produced by HFA Solution Inhalers", PORTABLE INHALERS, pp. 155-159, (November 26 & 27, 1998). Additional References sheet(s) attacks at the control of the control							sheet(s) attached
Examiner	Examiner Date Considered							
*Examiner: In	itial if r	eference is considered,	whether or not	citation is in conformance with MPEP 60	9; Draw lii	ne through	citation	if not in
Comornance	and no	or considered. Include co	by or ruis tom	with next communication to applicant.				

Modified	Form PTO 1449 U.S. DEPARTMENT OF COMMERCE			ATTY DOCKET NO.		SERIAL NO.			
David LEWIS et al FILING DATE GROUP 1616	(Modified)		PATENT AND TRAE	DEMARK OFFICE	239770US0DIV 10/612,067				
FILING DATE July 3, 2003				APPLICANT					
Sulp 3, 2003 1616	LIST OF REFERENCES CITED BY APPLICANT			David LEWIS et al					
U.S. PATENT DOCUMENTS	1				FILING DATE		GROUP		
DOCUMENT DATE NAME CLASS SUB FILING DATE NAME A3 622,053 11/23/71 John V. RYDEN A5 3,622,053 11/23/71 John V. RYDEN A7 4,835,145 D3/30/89 Peter MacDONALD A7 5,642,738 O7/10/87 Paul D. JAGER A7 5,642,728 O7/10/87 Jan ANDERSSON et al A7 5,642,728 O7/10/87 Jan ANDERSSON et al A7 5,642,728 O7/10/87 Jan ANDERSSON et al A7 6,605,674 O2/25/97 Terlochan S. PUREWAL et al A7 6,204,539 O3/60/91 Zahir SALDI et al A7 6,204,539 O3/60/91 Zahir SALDI et al A7 6,204,539 O3/60/91 Zahir SALDI et al A7 6,204,539 O3/60/91 A7 6,204,639 O3/60/91 O3/60/91 A7 6,204,639 O3/60/91	· .			July 3, 2003		1616			
NAME					U.S. PATENT DOCUMENTS				
AB 2003/0157028 A1 08/21/03 David LEW/IS et al				DATE	NAME CLASS				
AC		AA	3,622,053	11/23/71	John V. RYDEN				
AD 5,676,930 10/14/97 Paul D. JAGER		AB	2003/0157028 A1	08/21/03	David LEWIS et al				
AE 6,413,496 07/02/02 Michael GOODMAN et al		AC	4,835,145	05/30/89	Peter MacDONALD				
AF 5.642,728 D7/01/97 Jan ANDERSSON et al		AD	5,676,930	10/14/97	Paul D. JAGER				
AG 5,415,853		AE	6,413,496	07/02/02	Michael GOODMAN et al				
AH 5,605,674 02/25/97 Tarlochan S. PUREWAL et al AI 6,004,537 12/21/99 Frank E. BLONDINO et al AJ 6,241,969 05/05/01 Zahir SAIDI et al AK 2004/0047803 A1 03/11/04 David LEWIS et al AL 5,192,528 03/09/93 R. RADHAKRISHNAN et al AM 4,185,100 01/22/80 David T. ROVEE et al AN 6,253,762 07/03/01 Ignatius Loy BRITTO FOREIGN PATENT DOCUMENTS **FOREIGN PATENT DOCUMENTS** **DOCUMENT NUMBER** DATE COUNTRY TRANSLATION YES NO AO WO 93/05765 04/01/93 WIPO AP WO 93/18746 09/30/93 WIPO AP WO 93/18746 09/30/93 WIPO AR WO 93/11743 08/24/93 WIPO AR WO 93/11743 08/24/93 WIPO AS WO 98/01147 01/15/98 WIPO AT WO 98/13031 04/02/98 WIPO AT WO 98/13031 04/02/98 WIPO AT WO 90/35488 06/22/00 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX. The Aerosol Society, pp. 1-20, (December 14 & 15, 1998), AX International Journal of Pharmaceutics 1, 1978, pp. 71-83. AY B. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrocollororocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet. 1997, Col. 350, pp. 566-559. Date Considered *Examiner**		AF	5,642,728	07/01/97	Jan ANDERSSON et al				
AI 6,004,537 12/21/99 Frank E. BLONDINO et al		AG	5,415,853	05/16/95	Helmut HETTCHE et al				
AJ 6,241,969 05/05/01 Zahir SAIDI et al		АН	5,605,674	02/25/97	Tarlochan S. PUREWAL et al				
AK 2004/0047809 A1 03/11/04 David LEWIS et al		Al	6,004,537	12/21/99	Frank E. BLONDINO et al				
AL 5,192,528 03/09/93 R. RADHAKRISHNAN et al		AJ	6,241,969	06/05/01	Zahir SAIDI et al				
AM		AK	2004/0047809 A1	03/11/04	David LEWIS et al				
No.		AL	5,192,528	03/09/93	R. RADHAKRISHNAN et al				
DOCUMENT DATE COUNTRY TRANSLATION YES NO		AM	4,185,100	01/22/80	David T. ROVEE et al			-	
DOCUMENT NUMBER		AN	6,253,762	07/03/01	Ignatius Loy BRITTO				
NUMBER NO AO WO 93/05765 04/01/93 WIPO AP WO 93/18746 09/30/93 WIPO AQ WO 94/21229 09/29/94 WIPO AR WO 93/11743 06/24/93 WIPO AS WO 98/01147 01/15/98 WIPO AT WO 98/13031 04/02/98 WIPO AU WO 00/35458 06/22/00 WIPO AV WO 00/78286 12/28/00 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX, The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). S.S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet. 1997. AZ Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in			· · · · · · · · · · · · · · · · · · ·	FO	REIGN PATENT DOCUMENTS				
AO WO 93/05765 04/01/93 WIPO			DOCUMENT	DATE	COUNTRY			TRANSLATION	
AP WO 93/18746 09/30/93 WIPO AQ WO 94/21229 09/29/94 WIPO AR WO 93/11743 06/24/93 WIPO AS WO 98/01147 01/15/98 WIPO AT WO 98/13031 04/02/98 WIPO AU WO 00/35458 06/22/00 WIPO AV WO 00/78286 12/28/00 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX, The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). S.S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. AY L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Vol. 350, pp. 556-559. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in			NUMBER	DATE	COUNTRY		YES	S NO	
AQ WO 94/21229 09/29/94 WIPO AR WO 93/11743 06/24/93 WIPO AS WO 98/01147 01/15/98 WIPO AT WO 98/13031 04/02/98 WIPO AU WO 00/35458 06/22/00 WIPO AV WO 00/78286 12/28/00 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX. The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). AX Society, pp. 1-20, (December 14 & 15, 1998). AX International Journal of Pharmaceutics, 1, 1978, pp. 71-83. AY L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Vol. 350, pp. 556-559. Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in		AO	WO 93/05765	04/01/93	WIPO			<u> </u>	
AR WO 93/11743 06/24/93 WIPO AS WO 98/01147 01/15/98 WIPO AT WO 98/13031 04/02/98 WIPO AU WO 00/35458 06/22/00 WIPO AV WO 00/78286 12/28/00 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX, The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). AX S.S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. AX L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997. Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AP	WO 93/18746	09/30/93	WIPO				
AS WO 98/01147 01/15/98 WIPO AT WO 98/13031 04/02/98 WIPO AU WO 00/35458 06/22/00 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX, The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). S.S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm, Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Additional References sheet(s) attached Vol. 350, pp. 556-559. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AQ	WO 94/21229	09/29/94	WIPO				
AT WO 98/13031 04/02/98 WIPO AU WO 00/35458 06/22/00 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX, The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). S. S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Vol. 350, pp. 556-559. Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AR	WO 93/11743	06/24/93	WIPO				
AU WO 00/35458 06/22/00 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX, The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). S.S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Additional References sheet(s) attached Vol. 350, pp. 556-559. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AS	WO 98/01147	01/15/98	WIPO				
AV WO 00/78286 12/28/00 WIPO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX, The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). S.S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Additional References sheet(s) attached Vol. 350, pp. 556-559. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AT	WO 98/13031	04/02/98	WIPO				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX, The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). AX S.S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Vol. 350, pp. 556-559. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AU	WO 00/35458	06/22/00	WIPO				
B. Meakin, "Fine Particle Dose Control of Solution Based pMDIs", DRUG DELIVERY TO THE LUNGS IX, The Aerosol Society, pp. 1-20, (December 14 & 15, 1998). S.S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Vol. 350, pp. 556-559. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AV	WO 00/78286	12/28/00	WIPO				
AW Society, pp. 1-20, (December 14 & 15, 1998). S.S. DAVIS, "Physico-Chemical Studies on Aerosol Solutions For Drug Delievery I. Water-Propylene Glycol Systems", International Journal of Pharmaceutics, 1, 1978, pp. 71-83. L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. AZ P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Additional References sheet(s) attached Vol. 350, pp. 556-559. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in			OTHER R	FERENCES (Including Author, Title, Date, Pertinent	Pages, e	tc.)		
AX International Journal of Pharmaceutics, 1, 1978, pp. 71-83. L. Harrison et al, "Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Vol. 350, pp. 556-559. Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AW				IVERY TO	THE LUN	GS IX, The Aerosol	
AY Subjects", J. Pharm. Pharmacol., 1996, Vol. 48, pp. 596-600. P. Hoet et al, "Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Vol. 350, pp. 556-559. Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AX				ery I. Wate	er-Propyler	ne Glycol Systems",	
AZ used as ozone-sparing substitutes of chlorofluorocarbons", The Lancet, 1997, Vol. 350, pp. 556-559. Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in									
Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in		AZ	used as ozone-sparing			Addi	tional Refe	rences sheet(s) attached	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant	Examiner					Date Considered			
The same and the same are a same as a same a same as a same as a same a same a same a same a same a same a	*Examiner: In conformance	itial if r	eference is considered, ot considered. Include c	whether or not	citation is in conformance with MPEP 60 with next communication to applicant.	9; Draw lir	ne through	citation if not in	

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO.		SERIAL NO.				
(Modified)		PATENT AND TRAD	EMARK OFFICE	239770US0DIV 1			10/612,067		
			APPLICANT						
LIST OF RE	FER	ENCES CITED BY AP	PLICANT	David LEWIS et al					
				FILING DATE		GROUP			
				July 23, 2003		1616			
				U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
A	M	2003/0066525	04/10/03	David LEWIS et al					
Α	ιВ	6,716,414	04/06/04	David LEWIS et al					
A	C	2004/0062720	04/01/04	David LEWIS et al					
А	D.	4,499,108	02/12/85	Joel A. SEQUEIRA et al					
A	Æ	5,955,058	09/21/99	Paul Donald JAGER et al					
A	\F	6,150,418	11/21/00	Dieter HOCHRAINER et al					
A	G	6,315,985	11/13/01	Zheng Z. WU et al					
А	Ή	6,143,277	11/07/00	lan C. ASHURST et al			***		
Α	ΑI	2003-0089369	05/15/03	David LEWIS et al					
Α	۸J	6,045,784	04/04/00	Nicholas A. RUEBUSCH et al					
Α	ĸ	2005/0142071	06/30/05	David LEWIS et al			10		
A	\L	2006/0083693	04/20/06	David LEWIS et al					
А	М	2006/0120966	06/08/06	Tanya K. CHURCH et al					
А	N	2005/0129621	06/16/05	Rebecca J. DAVIES et al					
			FO	REIGN PATENT DOCUMENTS					
	T	DOCUMENT	T				TRANSLATION		
		NUMBER	DATE	COUNTRY		YES			
A	0	WO 99/65460	12/23/99	WIPO					
A	\P	0 642 992 A2	03/15/95	EPO (English Abstract provided)			XXX		
A	Q.	WO 98/24420	06/11/98	WIPO					
А	\R	0 372 777	06/13/90	EPO					
Α	\S	0 911 048	04/28/99	EPO					
Α	T	WO 99/12596	03/18/99	WIPO					
Α	U.	WO 92/20391	11/26/92	WIPO					
A	\V	WO 98/03533	01/29/98	WIPO					
		OTHER RE	FERENCES (Including Author, Title, Date, Pertinent	Pages, e	tc.)			
A	w	J. Daly, Jr., "Properties	and toxicolog	y of CFC alternatives", <u>Aerosol Age,</u> Feb	ruary 1990), pp. 26-21	7, 40, 56 and 57.		
A	w	D. Strobach, "Alternati	ves to CFCs" F	Part II, <u>Aerosol Age,</u> July 1988, pp. 32-33	, 42 and 4	3			
А				ection in Albuterol-Containing Metered-Do rnal of Pharmaceutical Sciences, 1997, \					
А				g MDI Formulation Development with rosol Medicine, 1991, Vol. 4, No. 3, pp.	Addi	tional Refe	erences sheet(s) attached		
Examiner					Date Considered				
*Examiner: Initial conformance and	l if re d not	ference is considered, considered. Include co	whether or not	citation is in conformance with MPEP 60 with next communication to applicant.	9; Draw lii	ne through	citation if not in		

Form PTO 1449 (Modified)		U.S. DEPARTMEN	T OF COMMERCE	ATTY DOCKET NO.		SERIAL NO.				
(Modified)		FAIENI AND IN	RDEIWIARK OFFICE	239770US0DIV	10/612,067					
				APPLICANT						
LIST OF	REFE	RENCES CITED BY A	PPLICANT	David LEWIS et al				·		
				FILING DATE		GROUP				
				July 3, 2003		1616				
				U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS			ING DATE PROPRIATE		
	AA	2005/0152846	07/14/05	Rebecca J. DAVIES et al						
	AB	4,584,320	04/22/86	David RUBIN et al						
	AC	5,776,433	07/07/98	Tsi-Zong TZOU et al						
	AD	4,579,854	04/01/86	Takeo IWAKUMA et al						
	AE									
	AF									
	AG									
	AH									
	Al									
	AJ		_							
	AK									
	AL		-							
	AM		1	-						
	AN									
			FO	REIGN PATENT DOCUMENTS		1				
		50011145117	1			I				
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO				
	AO	1 525 181	09/20/78	GB						
	AP	WO 96/19969	07/04/96	WIPO						
	AQ	WO 94/14490	07/07/94	WIPO						
	AR	WO 99/64014	12/16/99	WIPO						
	AS	WO 00/30608	06/02/00	WIPO						
	AT	WO 00/53157	09/14/00	WIPO						
	ΑU	WO 97/47286	12/18/97	WIPO						
	AV	2 326 334	12/23/98	GB						
				Including Author, Title, Date, Pertine	• .					
	AW	I. P. Tansey, "Chang Vol. 259, pp. 896-898		Inhalers: The Technical and Clinical C	hallenges",	The Pham	naceutica	<u>l Journal</u> , 1997,		
	AX		D. Tiwari et al, "Compatibility Evaluation of Metered-Dose Inhaler Valve Elastomers with Tetrafluoroethane (P134a), a Non-CFC Propellant, <u>Drug Development and Industrial Pharmacy</u> , 1998, Vol. 24, No. 4, pp. 345-352.							
	AY	Handbook of Pharma	Handbook of Pharmaceutical Excipients, 3rd Ed., Kibbe Editor, pp. 7-9, 220-222, 234-235 and 560-561.							
	AZ	Beclomethasone Fro	m Three Streng d-Dose Inhaler",	Skinetics and Dose Proportionality of Strengths of A CFC-Free Beclomethasone shaler", Biopharmaceutics & Drug Disposition, 643.						
Examiner					Date Considered					
*Examiner: In conformance	itial if r	reference is considered to considered. Include	d, whether or no copy of this form	t citation is in conformance with MPEP on with next communication to applicant.	609; Draw li	ne through	citation if	f not in		

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO.	SERIAL NO.				
(camou)	7712717710	EMPARK OFFICE	239770US0DIV 10/612,067					
LIST OF REFERENCES CITED BY APPLICANT			APPLICANT					
LIST OF REFERENCE	ES CITED BY API	PLICANT	David LEWIS et al	_				
			FILING DATE		GROUP			
			July 3, 2003		1616			
		· · · · · · · · · · · · · · · · · · ·	U.S. PATENT DOCUMENTS		-			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME CLASS				LING DATE PPROPRIATE	
AA								
AB								
AC								
AD								
AE								
AF								
AG								
AH								
At								
AJ								
AK								
AL								
AM	· N. V							
AN								
		FO	REIGN PATENT DOCUMENTS					
С	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO				
AO 0 653	3 204	05/17/95	EPO		160	<u>, </u>	110	
AP WOO	01/47493	07/05/01	WIPO					
AQ WO9	91/11173	08/08/91	WIPO					
AR WO9	93/11747	06/24/93	WIPO		-			
AS WO9	94/21228	09/29/94	WIPO					
AT WO9	96/18384	06/20/96	WIPO					
AU WO9	96/19198	06/27/96	WIPO					
AV WO9	96/19968	07/04/96	WIPO					
	OTHER RE	FERENCES (ncluding Author, Title, Date, Pertinent	Pages, e	c.)			
AW Chet Precli	Leach, "Enhance inical and Clinical	d Drug Deliver Programs", <u>R</u> e	y Through Reformulating MDIs with HFA espiratory Drug Delivery V, 1996, pp. 133	Propellant 3-144.	s-Drug De	position	and Its Effect on	
AX Decei	ambilla et al, "Moo mber 14-15, 1998	dulation of Aer , The Aerosol	osol Clouds Produced By HFA Solution I Society.	nhalers", <u>C</u>	rug Delive	ery to The	e Lungs,	
AY								
AZ				Addi	tional Refe	rences s	sheet(s) attached	
Examiner				Date Cor	Date Considered			
*Examiner: Initial if reference conformance and not consi	ce is considered, idered. Include co	whether or not	citation is in conformance with MPEP 60 with next communication to applicant.	9; Draw lir	ne through	citation	if not in	

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO.	SERIAL NO.				
(Modified)	PATENT AND TRA	DEMARK OFFICE	239770US0DIV	10/612,067				
LIOT OF DEFENDENCES SITED BY APPLICANT			APPLICANT					
LIST OF REF	ERENCES CITED BY AF	PLICANT	David LEWIS et al					
			FILING DATE		GROUP			
			July 3, 2003		1616			
			U.S. PATENT DOCUMENTS	,				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIA		
AA		4						
AB								
AC								
AD								
AE								
AF								
AG		-						
AH		 						
Al						· · · · · · · · · · · · · · · · · · ·		
AJ								
AN								
AL				1				
AN								
AN		1						
		F0	REIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY		YES	TRANSLATION NO		
AC	WO 98/05302	02/12/98	WIPO					
AP	WO 00/07567	02/17/00	WIPO					
AC	WO 98/34596	08/13/98	WIPO					
AR	WO 94/13262	06/23/94	WIPO					
AS	WO 00/06121	02/10/00	WIPO					
AT	WO 99/65464	12/23/99	WIPO					
AU	WO 00/23065	04/27/00	WIPO					
AV	WO 96/32099	10/17/96	WIPO					
	OTHER R	EFERENCES (Including Author, Title, Date, Pertinent	Pages, e	tc.)			
AW								
AX								
AY								
AZ				Addi	tional Refe	rences sheet(s) atta	ached	
Examiner				Date Cor	nsidered		T	
*Examiner: Initial i	reference is considered not considered. Include o	, whether or no copy of this form	t citation is in conformance with MPEP 60 n with next communication to applicant.	9; Draw li	ne through	citation if not in		

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO.			SERIAL NO.			
		TALENT AND THE	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						10/612,067	
LIST OF	DEFE	DENICES CITED BY A	DI ICANT	APPLICANT						
LISTOF	KEFE	RENCES CITED BY AF	PLICANI	David LEWIS et al						
				FILING DATE			GROUP			
				July 3, 2003			1616	_		
				U.S. PATENT DOCUMENT	'S					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME CLASS			S SUB FILING DATE IF APPROPRIATE			
	AA									
	AB		<u> </u>							
	AG									
	AD									
	AE									
	AF		ļ							
	AG		ļ							
	AH		ļ							
	Al		ļ							
	AJ									
	AK									
	AL									
	AM									
	AN		<u> </u>	L						
		T	FC	REIGN PATENT DOCUME	NTS					
		DOCUMENT NUMBER	DATE	COUN	TRY		YES		LATION NO	
	AO	WO 01/89480	11/29/01	WIPO						
	AP	1 157 689	11/28/01	EPO						
	AQ	WO 03/074023	09/12/03	WIPO						
	AR									
	AS									
	AT									
	AU									
	AV									
		OTHER R	EFERENCES	Including Author, Title, Da	ate, Pertinent P	ages, et	tc.)			
	AW									
	AX									
	AY									
	AZ]	Addi	tional Refe	erences	sheet(s) attached	
Examiner						Date Considered				
				t citation is in conformance n with next communication t		Draw lin	ne through	citation	if not in	